Your cart is currently empty!
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered Alteogen Inc. to develop and commercialize subcutaneous versions of an undisclosed cancer drug using Alteogen’s recombinant hyaluronidase enzyme, ALT-B4. This collaboration aims to expand AstraZeneca’s oncology portfolio by leveraging Alteogen’s innovative technology for improved drug…
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
•
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical Products Administration for its Winrevair (sotatercept-csrk) to be imported by Shanghai Ruijin Hospital’s Hainan subsidiary. This approval is significant as it provides a new treatment option for patients with pulmonary arterial hypertension (PAH) in China.…
Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
•
Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in Chinese patients with familial chylomicronemia syndrome (FCS). The trial successfully met its primary efficacy endpoint and all key secondary endpoints, marking a significant advancement in the treatment of this rare lipid disorder. Study Details and…
ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
•
China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control equipment, an innovative product now eligible for clamping and pulling diseased tissues during submucosal dissection of esophagus and stomach endoscopy. Product InnovationThis product, the first home-grown digestive endoscopic integrated robot in China, features a flexible…
Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific
•
Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer Inc. (NYSE: PFE), has achieved significant sales milestones in the Asia Pacific region and China. This performance has triggered a milestone payment of USD2.5 million to Basilea. Drug Profile and CommercializationCresemba, co-developed with Japan’s Astellas…
Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy
•
California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center in Tianjin, China. This strategic move underscores the company’s commitment to advancing Danaher Corporation’s (NYSE: DHR) “Launching China” strategy. Strategic IntegrationAs a member of Danaher Corporation’s Life Science Platform, Phenomenex aims to leverage the quality…
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
•
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European Commission (EC) for its Breyanzi (lisocabtagene maraleucel; liso-cel). The approval allows the drug to be used in adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Clinical…
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
•
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and…
Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection
•
Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET radiopharmaceuticals, and St. Teresa’s Hospital, a private hospital in Hong Kong, announced the launch of Neuraceq (florbetaben (18F)) in Hong Kong this month. This marks a significant advancement in the diagnosis and management of Alzheimer’s…
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
•
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA) to initiate a clinical study for its FT-003, a recombinant adeno-associated virus (rAAV) gene therapy for diabetic retinopathy (DR). This follows previous approvals for studies in neovascular age-related macular degeneration (nAMD) and diabetic macular edema…
Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China
•
US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced last week that it has obtained marketing approval from China’s National Medical Products Administration (NMPA) for its peripheral vein thrombectomy stent system. This marks a significant milestone in the company’s global expansion strategy. Product DetailsThe…
Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its tegileridine. The Category 1 drug is now approved to treat postoperative moderate to severe pain. Drug Profile and MechanismTegileridine is a μ opioid receptor (MOR)-biased small-molecule agonist. It…
Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval
•
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products Administration (NMPA) for its Category 1 drug DM002. This marks a significant milestone in the development of the company’s innovative bispecific antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3) and mucin…
MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment
•
Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has received marketing approval from China’s National Medical Products Administration (NMPA). The approval is for the minimally invasive interventional treatment of thoracic aortic dissection involving branches of the aortic arch. Product InnovationThe Cratos system represents an…
Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment
•
China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its PD-1 inhibitor penpulimab (AK105). The drug is now approved for use in combination with chemotherapy for first-line recurrent or metastatic nasopharyngeal carcinoma (NPC). Commercialization and Market PresencePenpulimab, a differentiated PD-1 therapy,…
Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease
•
China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume (teprotumumab), a recombinant anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, has been approved by China’s National Medical Products Administration (NMPA). This approval marks Sycume as China’s first and the world’s second approved IGF-1R antibody drug,…
Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment
•
Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA) for ADC189, their co-developed anti-influenza drug, has been accepted for review by China’s National Medical Products Administration (NMPA). The drug is intended for treating uncomplicated influenza A and B in adults and adolescents. Mechanism and…
Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies
•
Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company’s proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas. Investor Support…
Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation
•
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy the implementation of the DeepSeek R1 large model, chaired by Chairman Zhang Yufu. The company aims to accelerate the development and commercialization of the SPT-07A project through AI technology, marking a significant step in its…
Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development
•
Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan Kefeng Changjian Pharmaceutical Technology Co., Ltd. (Kefeng Changjian) to advance the development and commercialization of the SPT-07A project. Collaboration DetailsThe agreement, based on the principle of equality and mutual benefit, aims to accelerate the speed…
